Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07602777 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 43% 113 → 64 participants
See other at-risk trials from GlaxoSmithKline

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment reduced: 113 → 64 participants Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Trial sites expanded: 6 → 13 locations
    • Primary completion date: Nov 18, 2027 to Nov 5, 2027
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 13 of 16 entries
  2. Recruitment openedv2 Show 4 more changesShow less
    • Trial sites expanded: 0 → 6 locations
    • Primary completion date: Dec 10, 2027 to Nov 18, 2027
    • Study completion date: Dec 17, 2029 to Nov 23, 2029
    • Start date changed from estimate of Jul 14, 2026 to Jun 22, 2026
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
Sarcoma
1,026 trials monitored
See 67 trials at risk
The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it, and how their bodies handle the drug (how its absorbed and broken down). This research is for adolescents and adults who have either: Osteosarcoma, which is a type of bone cancer, or Soft Tissue Sarcoma, which is a type of cancer that starts in soft body tissues (like muscle, fat, or nerves). In both cancer types the cancer must have already been treated, but has come back or spread, and cant be removed by surgery
Trial Details
NCT Number NCT07602777
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Sarcoma
Related terms Sarcoma
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov